Oncorena

Biotech · Stockholm, SE

Pharmaceutical company developing orellanine-based treatment for advanced kidney cancer.

Funding history

Date	Round	Amount
Dec 2021	Funding round Oncorena, a Swedish kidney-cancer drug developer, secured SEK 66M to fund its first clinical study.	$7.6M